All In Biotech

NDA 050441 · Pfizer

Cleocin Phosphate

Clindamycin Phosphate · Injection

Last checked: Nov 19, 2026Latest source record: Mar 26, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1972

Oct 2, 1972

Approved uses

1

Original approval plus efficacy supplements

Registered trials

274

66 Phase 3, 28 recruiting

FAERS reports

3,596

2,284 serious, 270 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING WARNING Clostridioides difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including CLEOCIN PHOSPHATE and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. Because CLEOCIN PHOSPHATE therapy has been associated with severe colitis which may end fatally, it should be reserved for serious infections where less toxic antimicrobial agents are inappropriate, as described in the INDICATIONS AND USAGE section. It should not be used in patients with nonbacterial infections such as most upper respiratory tract infections. C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be...

What it is approved for

From the label in effect Oct 27, 2026.

INDICATIONS AND USAGE CLEOCIN PHOSPHATE products are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. CLEOCIN PHOSPHATE products are also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the BOXED WARNING , before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. CLEOCIN PHOSPHATE is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 2, 1972 Original approval
1 products under this application
  • CLEOCIN PHOSPHATE · CLINDAMYCIN PHOSPHATE EQ 150MG BASE/ML · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Clindamycin" as an intervention, any sponsor and status, largest first.

All 274 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective373
  • rash259
  • drug hypersensitivity231
  • off label use228
  • diarrhoea192
  • nausea190
  • fatigue171
  • pruritus169
  • pain164
  • condition aggravated135
  • dyspnoea116
  • headache114

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200419
200553
200659
200714
200820
200943
201086
201166
201299
2013102
2014103
2015125
2016246
2017184
2018237
2019281
2020210
2021194
2022288
2023305
2024287
2025309
2026264

Recalls

4 FDA enforcement reports for this application.

  • Mar 15, 2019 · Class III · Terminated

    Failed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demonstrated for several specified impurities at the 24-month time point

  • Mar 15, 2019 · Class III · Terminated

    Failed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demonstrated for several specified impurities at the 24-month time point

  • Mar 15, 2019 · Class III · Terminated

    Failed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demonstrated for several specified impurities at the 24-month time point

  • Jun 4, 2013 · Class II · Terminated

    Presence of Particulate Matter: Firm is recalling a small number of vials with very small reflective flakes consistent with delamination of the glass vial.

Shortages

FDA's drug shortage list.

  • Current · updated Nov 6, 2026

    Cleocin Phosphate, Injection, Cleocin Phosphate 600 mg/4 mL (150 mg/mL) (NDC 0009-0775-26). Other

  • To Be Discontinued · updated Jun 1, 2026

    Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL); 4 mL Vial (NDC 0009-0775-26). Discontinuation of the manufacture of the drug

  • To Be Discontinued · updated Jun 1, 2026

    Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL); 4 mL Vial NovaPlus (NDC 0009-4073-04). Discontinuation of the manufacture of the drug

  • To Be Discontinued · updated Jun 1, 2026

    Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL); 6 mL Vial (NDC 0009-0902-18). Discontinuation of the manufacture of the drug

  • To Be Discontinued · updated Jun 1, 2026

    Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL); 2 mL Vial (NDC 0009-0870-26). Discontinuation of the manufacture of the drug

  • Current · updated Nov 6, 2026

    Cleocin Phosphate, Injection, Cleocin Phosphate 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18). Other

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cleocin Phosphate (Clindamycin Phosphate)

2024 spending

$9K

Beneficiaries

80

164 claims

Per beneficiary

$115

$0.53 per unit

View as table
YearSpending
2020$11,801
2021$8,274
2022$3,360
2023$715
2024$9,204

Part B: Cleocin Phosphate* (Clindamycin Phosphate*) · HCPCS J0736

2024 spending

$69K

Beneficiaries

11,748

12,338 claims

Per beneficiary

$6

2024 ASP limit $2.26 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$981
2024$68,958

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,207 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.